Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes

9 de noviembre de 2012 actualizado por: Soo-Wan Chae, Chonbuk National University Hospital

Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.

This trial is being conducted to look for following changes when Korean traditional diets is taken in subjects with hypertension and type 2 diabetes:

To evaluate the improvement of the controlling fasting blood glucose and glycated hemoglobin.

To assess the controlling blood pressure and heart rate.

To evaluate the influence on cardiovascular risk factor, Triglyceride, cholesterol, High Density Lipoprotein-cholesterol and Low-Density Lipoprotein-cholesterol.

To evaluate the influence on Gamma-Glutamyl Transpeptidase.

To evaluate the influence on Cardiovascular risk factor.

To evaluate the influence on valsava score, breathing score and upright score.

Descripción general del estudio

Descripción detallada

The investigators aimed to investigate the efficacy of Korean traditional diets in controlling fasting blood glucose fluctuation, blood pressure, and cardiovascular risk factors in hypertensive and type 2 diabetic patients who were taking medications prescribed for respective diseases in a 12-week.

Tipo de estudio

Intervencionista

Inscripción (Actual)

48

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Jeollabuk-do
      • Jeonju, Jeollabuk-do, Corea, república de, 560-822
        • Clinical Trial Center for Functional Foods; Chonbuk National University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Subjects who are men and women volunteers 19~80years
  • Subject who have hypertension and type 2diabetes.
  • Subject who have taking oral medications :

(hypoglycemic, blood pressure and lipid modifying drugs).

  • Subject must provide written informed consent to participate in the study.

Exclusion Criteria:

  • Subject with a history or evidence of clinically significant gastrointestinal,anorectal, hepatic, renal, neurological, pulmonary, endocrine, blood tumor,psychiatric.
  • Hypertension(DBP>116mmHg or SBP>200 mmHg) having the history of cardiovascular events or taking medications known to affect lipoprotein metabolism.
  • Having Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (HbA1c >9.0%).
  • Subjects with the history of cancer.
  • Subjects who have a gastrointestinal (GI) disease (Crohn's disease, etc.) that would increase the influence with absorbance medication or a GI surgery excluding appendectomy and hernia surgery.
  • Having digestive, or central nervous system disorders.
  • Subject is hematologic, or neuroretinopathy.
  • Subject with uterine fibroids at ultrasonography.
  • Having severe or malignant retinopathy.
  • Having the impairment of renal and liver function, dysproteinemia, nephritic syndrome, or other renal disease.
  • Having coagulopathy
  • Having human immunodeficiency virus.
  • Having the history of mental instability and of drug and alcohol.
  • Having the history of reactions to our experimental products.
  • Participating in other clinical trials within the past 2 months.
  • Having laboratory tests, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study.
  • Having the history of alcohol or substance abuse.
  • Subject is pregnant, planning to become pregnant, or breast-feeding.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Korean traditional diets
Korean traditional diets (calorie 2,100kcal) for 12weeks

The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.

The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.

Otros nombres:
  • The Korean Traditonal diets
Comparador activo: Control group
Control group : told to "eat as usal diet) for 12weeks
Told to " eat as usal diets".
Otros nombres:
  • Control diets

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
HbA1C :Glycated Hemoglobin
Periodo de tiempo: 84days
Glycated Hemoglobin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
TG :Triglycerides
Periodo de tiempo: 84days
Triglycerides is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
TC :Total cholesterol
Periodo de tiempo: 84days
Total cholesterol is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
HDL-C :High Density Lipoprotein-Cholesterol
Periodo de tiempo: 84days
HDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
LDL-C : Low Density Lipoprotein-Cholesterol
Periodo de tiempo: 84days
LDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Breathing score
Periodo de tiempo: 84days
Breathing score is measured in study visits to the clinic, week 0(baseline)and week 12.
84days
Valsalva score
Periodo de tiempo: 84days
Valsalva score is measured in study visits to the clinic, week 0(baseline)and week 12.
84days
Upright score
Periodo de tiempo: 84days
Upright score is measured in study visits to the clinic, week 0(baseline) and week 12.
84days
ApoA1 :Apolipoprotein A1
Periodo de tiempo: 84days
Apolipoprotein A1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
ApoB :Apolipoprotein B
Periodo de tiempo: 84days
Apolipoprotein B is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Apo E :Apolipoprotein E
Periodo de tiempo: 84days
Apolipoprotein E is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Free fatty acid
Periodo de tiempo: 84days
Free fatty acid is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Adiponectin
Periodo de tiempo: 84days
Adiponectin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
PAI-1 :Plasminogen activator inhibitor type 1
Periodo de tiempo: 84days
PAI-1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Homocysteine
Periodo de tiempo: 84days
Homocysteine is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
FPG :Fasting plasma glucose
Periodo de tiempo: 84days
Fasting plasma glucose is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
DBP:Diastolic Blood Pressure
Periodo de tiempo: 84days
DBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
SBP:Systolic Blood Pressure
Periodo de tiempo: 84days
SBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Heart rate
Periodo de tiempo: 84days
Heart rate is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
weight
Periodo de tiempo: 84days
weight is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
BMI:Body Mass Index
Periodo de tiempo: 84days
BMI is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Body fat percent
Periodo de tiempo: 84days
Body fat percent is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Waist
Periodo de tiempo: 84days
Waist is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
84days
Obesity associated gut microbiome(Bacteriodetes)
Periodo de tiempo: 84days
Bacteriodetes is measured in study visits to the clinic, week 0(baseline)and week 12.
84days
Obesity associated gut microbiome(Firmicutes)
Periodo de tiempo: 84days
Firmicutes is measured in study visits to the clinic, week 0(baseline)and week 12.
84days
Hypoglycemic(oral medication)
Periodo de tiempo: 84days
Hypoglycemic oral medication is measured in study 0wk, 4wk, 8wk and 12wk.
84days
Control blood pressure(oral medication)
Periodo de tiempo: 84days
Control blood pressure(oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
84days
Lipid modifying (oral medication)
Periodo de tiempo: 84days
Lipid modifying (oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
84days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de septiembre de 2010

Finalización primaria (Actual)

1 de enero de 2011

Finalización del estudio (Actual)

1 de febrero de 2011

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2012

Primero enviado que cumplió con los criterios de control de calidad

9 de noviembre de 2012

Publicado por primera vez (Estimar)

12 de noviembre de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

12 de noviembre de 2012

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2012

Última verificación

1 de noviembre de 2012

Más información

Términos relacionados con este estudio

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Diabetes Mellitus, Tipo 2

Ensayos clínicos sobre Korean traditional diets

3
Suscribir